General Medicine
Ozempic (semaglutide) is a prescription GLP-1 receptor agonist used for specific medical indications. Gastrointestinal symptoms are common, while pancreatitis, gallbladder disease, kidney injury from dehydration, diabetic retinopathy complications, severe gastrointestinal reactions and serious allergic reactions are among the important risks listed in current prescribing information.
The most common Ozempic side effects are nausea, vomiting, diarrhoea, abdominal pain and constipation. More serious problems can include acute pancreatitis, gallbladder disease, diabetic retinopathy complications, acute kidney injury related to volume depletion, severe gastrointestinal adverse reactions and serious hypersensitivity reactions. The current FDA label also contains a boxed warning about thyroid C-cell tumors based on rodent data; whether this risk applies to humans is unknown.

Add My Health Hospitals as a Preferred Source on Google to see more of our latest health information.
Ozempic is the brand name for semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. It helps lower blood glucose by increasing insulin secretion when blood glucose is elevated and reducing glucagon secretion. It also slows gastric emptying and can reduce appetite.
In the current U.S. FDA label, Ozempic is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It also has cardiovascular and kidney-risk reduction indications for specific adults with type 2 diabetes and established cardiovascular disease or chronic kidney disease.
Semaglutide slows gastric emptying and changes appetite and gastrointestinal signalling. These effects can contribute to nausea and other digestive symptoms. Gastrointestinal adverse reactions are particularly relevant during treatment initiation and dose escalation.
If nausea is persistent, severe or prevents you from keeping fluids down, contact your doctor rather than changing or stopping the dose yourself.
| Potential problem | Warning symptoms | What to do |
|---|---|---|
| Acute pancreatitis | Severe or persistent upper abdominal pain, sometimes extending to the back, with or without vomiting. | Seek urgent medical assessment. The FDA label says Ozempic should be discontinued if pancreatitis is suspected. |
| Gallbladder disease | Upper-right or upper abdominal pain, fever, nausea or jaundice. | Prompt medical evaluation may be needed. |
| Severe gastrointestinal reactions | Persistent vomiting, severe abdominal symptoms or inability to tolerate food and fluids. | Contact your doctor promptly. Ozempic is not recommended in people with severe gastroparesis. |
| Acute kidney injury from volume depletion | Reduced urination, weakness or dizziness after significant vomiting or diarrhoea. | Seek medical advice, especially if fluid intake is poor or symptoms are worsening. |
| Serious allergic reaction | Swelling of the face, lips, tongue or throat, hives or trouble breathing. | Seek emergency medical care immediately. |
| Diabetic retinopathy complications | New or worsening vision changes. | Contact your doctor or eye-care professional promptly. |
The current FDA prescribing information carries a boxed warning for thyroid C-cell tumors. In rodents, semaglutide caused thyroid C-cell tumors. It is unknown whether Ozempic causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans.
Ozempic is contraindicated for people with a personal or family history of MTC or people with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Persistent neck swelling or a neck mass, trouble swallowing, trouble breathing or persistent hoarseness should be medically assessed.
Acute pancreatitis has been observed with GLP-1 receptor agonists, including Ozempic. Severe or persistent abdominal pain, especially when accompanied by vomiting, requires prompt medical evaluation.
Acute gallbladder disease is included in the Ozempic warnings. Gallstones and inflammation of the gallbladder may require evaluation if symptoms suggest a biliary problem. Upper abdominal pain with fever, vomiting or jaundice should not be ignored.
Diabetic retinopathy complications were reported in an Ozempic clinical trial. The FDA label advises monitoring patients with a history of diabetic retinopathy for progression. Rapid improvement in glucose control can be associated with temporary worsening of diabetic retinopathy in some settings.
Acute kidney injury can occur, particularly when significant vomiting or diarrhoea causes dehydration and volume depletion. Seek medical assessment if fluid intake is poor, urine output falls significantly or symptoms are worsening.
The risk of hypoglycemia increases when Ozempic is used with insulin or an insulin secretagogue such as a sulfonylurea. Medication adjustments may be required under medical supervision. Symptoms can include sweating, shakiness, hunger, dizziness, confusion and weakness.
Ozempic delays gastric emptying and can cause gastrointestinal adverse reactions. The current FDA label says Ozempic is not recommended in patients with severe gastroparesis. Persistent vomiting, early fullness, marked bloating or difficulty maintaining nutrition and hydration require medical assessment.
Gastrointestinal symptoms may become more noticeable when the dose is increased. The FDA prescribing information uses gradual dose escalation to reduce gastrointestinal adverse reactions. Do not increase the dose faster than prescribed, and do not make dose changes based on online advice.
Do not stop Ozempic or change the dose without discussing it with the prescribing clinician. If it is being used to manage type 2 diabetes, stopping treatment may worsen glucose control. The best transition depends on the reason for treatment, current glucose levels, other medicines and individual risk factors.
Ozempic contains semaglutide, but semaglutide products do not all have the same approved indications. The current U.S. Ozempic label covers specific type 2 diabetes-related indications; chronic weight-management indications are associated with other semaglutide labeling. Product indications can differ by country. Patients should not assume that an Ozempic prescription for weight loss is equivalent to a locally approved weight-management indication.
WHO's guidance supports GLP-1 therapies as one component of long-term obesity management for adults with obesity, alongside lifestyle and health-professional support. It does not recommend these medicines for everyone and excludes pregnant women from that guideline.
The current U.S. prescribing information recommends discontinuing Ozempic in women at least 2 months before a planned pregnancy because semaglutide has a long washout period. Pregnancy-related decisions should be discussed with the treating doctor.
Compounded semaglutide is not the same as an FDA-approved Ozempic pen. The FDA has reported dosing errors and adverse events with compounded injectable semaglutide products, including gastrointestinal effects, dehydration, pancreatitis and gallstones. Patients should verify the exact product and dose with a qualified healthcare professional.
If you are using semaglutide for diabetes and are experiencing nausea, vomiting, abdominal pain, constipation, diarrhoea, dizziness, vision changes or other new symptoms, a General Medicine or Diabetology consultation can help assess whether the symptoms are medication-related and whether treatment changes are appropriate.
My Health Hospitals lists Dr. Ch. Srujith as a General Physician & Diabetologist at Kukatpally, Hyderabad, with MBBS and MD – General Medicine. The supplied hospital profile lists 11 years of overall experience and appointment phone +91 9111674111; current availability should be confirmed before visiting.

General Medicine physician at My Health Hospitals, Kukatpally, Hyderabad, with adult medical and diabetes care practice.
Add My Health Hospitals as a Preferred Source on Google to see more of our latest health information.
Severe abdominal pain, repeated vomiting, dehydration, vision changes or other concerning symptoms should be assessed rather than managed through online advice alone.
My Health Hospitals – Kukatpally: +91 9111674111
Find the Best Hospital Near You
H.No 15-24-212, MIG-212, Rd Number 1, K P H B Phase 1, Kukatpally, Hyderabad, Telangana 500072
H.No:-12-5-30, WhiteHouse, Moula Ali Rd, South Lalaguda, Tarnaka, Secunderabad, Telangana 500017